Scinai Immunotherapeutics (SCNI) M&A Announcement summary

Deal rationale and strategic fit

• Entered a binding option agreement to acquire an Italian biotech, aiming to advance PC111, a novel antibody for rare dermatological diseases such as pemphigus and SJS/TEN.

• PC111 offers a unique, non-immunosuppressive mechanism targeting sFasL, addressing unmet needs in severe dermatological conditions.

• The acquisition supports expansion into rare disease therapeutics, aligning with strategic innovation in dermatology.

Financial terms and conditions

• A joint grant application was submitted to the Polish government for €12 million in non-dilutive funding to support PC111 development.

• Full development program financing is estimated at €55 million, structured with go/no-go decision points to manage risk.

• Potential peak revenues for PC111 are estimated at $490M (pemphigus) and $520M (SJS/TEN), with broader ranges up to $1.27B depending on market and pricing strategies.

• Pricing models consider US and international markets, with premiums over existing therapies like Rituximab.

Synergies and expected cost savings

• The merger brings together scientific, clinical, and commercial expertise from both teams, enhancing drug development and market access.

• PC111's rapid, targeted action may reduce reliance on steroids and immunosuppressants, potentially lowering long-term treatment costs and side effects.

• Collaboration enables efficient clinical trial site identification and protocol design through advisory boards and networks.